Chapter 6 of 25
What you will learn
- Understand ultrasound, office biopsy, hysteroscopy and curettage.
- Prepare for pain control and informed consent.
- Know what to do after an inadequate or reassuring result if symptoms persist.
Clinical assessment
The clinician asks about bleeding, menstrual or menopausal status, pregnancy possibility, medicines and family history. Examination can help identify whether bleeding comes from the uterus, cervix, vagina or another site. You can request an explanation before each step, a chaperone, adjustments for trauma or discomfort, and an opportunity to pause. An intimate examination should not proceed without consent.
Transvaginal ultrasound uses a probe placed in the vagina to examine the uterus and ovaries. It may show thickening, a polyp, fibroids or other abnormalities. If this approach is unsuitable, alternatives can be discussed, although they may provide different detail. In menstruating patients, normal lining thickness changes across the cycle; there is no simple universal thickness cutoff that rules cancer in or out.
Why a thin lining is not a universal all-clear
ACOG's 2026 guidance recommends ultrasound plus tissue sampling for most patients with postmenopausal bleeding. Selected low-risk patients with a single episode, a fully visualized lining of 4 mm or less and prompt access to follow-up may be assessed initially with ultrasound alone. This exception should be agreed with a clinician. Persistent bleeding, concerning risk factors or poor visualization require a different assessment.
Some aggressive cancers occur with little visible thickening. A scan described as normal does not cancel symptoms. Likewise, cervical screening samples the cervix, not the endometrium. A normal Pap or HPV result is not an endometrial diagnostic test.
Sampling methods
| Method | What happens | Main limitation or consideration |
|---|---|---|
| Office endometrial biopsy | A thin tube passes through the cervix to sample lining | Cramping; sample may be insufficient or miss a focal lesion |
| Hysteroscopy with biopsy | A small camera views the cavity and guides sampling | Requires a pain-control plan; setting varies |
| Dilatation and curettage | Cervix is opened and tissue removed, often with hysteroscopy | May need anaesthesia; not a reason to omit direct visualization when indicated |
Before sampling, discuss pain relief, local anaesthesia or sedation options where appropriate. Tell the team about anticoagulants, allergies and possible pregnancy. Mild cramping or spotting can occur afterwards. Seek advice for heavy bleeding, fever, worsening pain or offensive discharge according to the team's instructions.
Understanding the result
A report may show benign tissue, a polyp, hyperplasia, EIN, cancer or insufficient tissue. “Insufficient” means the sample cannot answer the question adequately; it is not equivalent to “no cancer.” If a benign result does not explain ongoing bleeding, further assessment may include hysteroscopy and directed sampling. The plan depends on the whole clinical picture.
If cancer is found, the report identifies histology and often grade. Molecular tests may follow as an addendum. The final hysterectomy specimen can refine the diagnosis because it contains more tissue. Referral to a gynaecological oncology team allows surgery and further investigations to be coordinated rather than arranged in isolation.
Questions and take-home messages
Ask how discomfort will be managed, when results should arrive, whether the sample was adequate and what to do if bleeding continues. Do not assume silence means a normal result. A written contact route and a named person responsible for communicating pathology are useful safeguards. Tests should answer a clinical question; repeating scans without resolving persistent symptoms is not a substitute for appropriate sampling.
Related chapters
- Imaging and Staging Investigations
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- ACOG updated postmenopausal bleeding guidance, April 2026
- ACOG Clinical Consensus: EIN / atypical hyperplasia, 2023
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy